Display options
Cite
Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1(1):e000034doi: 10.1136/rmdopen-2014-000034.
Salmon, J. H., Cacoub, P., Combe, B., Sibilia, J., Pallot-Prades, B., Fain, O., Cantagrel, A., Dougados, M., Andres, E., Meyer, O., Carli, P., Pertuiset, E., Pane, I., Maurier, F., Ravaud, P., Mariette, X., & Gottenberg, J. E. (2015). Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD open, 1(1), e000034. https://doi.org/10.1136/rmdopen-2014-000034
Salmon, J H, et al. "Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry." RMD open vol. 1,1 (2015): e000034. doi: https://doi.org/10.1136/rmdopen-2014-000034
Salmon JH, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O, Cantagrel A, Dougados M, Andres E, Meyer O, Carli P, Pertuiset E, Pane I, Maurier F, Ravaud P, Mariette X, Gottenberg JE. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015 Jun 30;1(1):e000034. doi: 10.1136/rmdopen-2014-000034. eCollection 2015. PMID: 26509060; PMCID: PMC4612695.
Copy Download .nbib Format: NLM
Share it on

RMD Open. 2015 Jun 30;1(1):e000034. doi: 10.1136/rmdopen-2014-000034. eCollection 2015.

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.

RMD open

J H Salmon, P Cacoub, B Combe, J Sibilia, B Pallot-Prades, O Fain, A Cantagrel, M Dougados, E Andres, O Meyer, P Carli, E Pertuiset, I Pane, F Maurier, P Ravaud, X Mariette, J E Gottenberg

Affiliations

  1. Rheumatology Department, CHU Reims, Reims, France.
  2. Departement Hospitalo-Universitaire I2B, UPMC Univ Paris 06, CNRS, UMR 7211, INSERM, UMR_S 959, Department of Internal Medicine, Groupe Hospitalier Pitié-Salpêtrière (AP-HP), Paris, France.
  3. Rheumatology Department, Lapeyronie University Hospital, Montpellier I, University, UMR5535, Montpellier, France.
  4. Rheumatology department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, INSERM UMRS_1109, Université de Strasbourg, Strasbourg, France.
  5. Rheumatology Department, CHU Saint-Etienne, Saint-Etienne, France.
  6. Department of Internal Medicine, Hôpital Jean Verdier, Bondy, France.
  7. Rheumatology Center, Purpan Hospital, Paul Sabatier University, Toulouse, France.
  8. Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France.
  9. Department of Internal Medicine, University Hospital of Strasbourg, Strasbourg, France.
  10. Rheumatology Department, GroupeHospitalier Bichat-Claude Bernard (AP-HP), Paris, France.
  11. Department of Internal Medicine, Hôpital D'Instruction des Armeés Sainte-541 Anne, Toulon, France.
  12. Rheumatology Department, CH René Dubos, Pontoise, France.
  13. Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France.
  14. Department of Internal Medicine, CHR Metz, Metz, France.
  15. Rheumatology Department, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM U1184, IMVA: Center of Immunology of Viral Infections and Autoimmune Diseases, Paris, France.
  16. Rheumatology Department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, CNRS, Institut de Biologie Moléculaire et Cellulaire, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Université de Strasbourg, Strasbourg, France.

PMID: 26509060 PMCID: PMC4612695 DOI: 10.1136/rmdopen-2014-000034

Abstract

OBJECTIVES: To evaluate the prevalence of late-onset neutropenia and its complications in patients treated with rituximab (RTX) for rheumatoid arthritis (RA) and other autoimmune diseases (AIDs) in a prospective registry.

METHODS: The AutoImmunity and Rituximab registry is an independent 7-year prospective registry promoted by the French Society of Rheumatology. For each episode of neutropenia, data were validated by the clinician in charge of the patient.

RESULTS: Among 2624 patients treated with RTX for refractory AIDs, and at least 1 follow-up visit (a total follow-up of 4179 patient-years in RA and 987 patient-years in AIDs), late-onset neutropenia was observed in 40 patients (25 RA (1.3% of patients with RA, 0.6/100 patient-years), and AIDs in 15 (2.3% of patients with AIDs, 1.5/100 patient-years)). 6 patients (15%) had neutrophils <500/mm(3), 8 (20%) had neutrophils between 500 and 1000/mm(3), and 26 (65%) had neutrophils between 1000 and 1500/mm(3). Neutropenia occurred after a median period of 4.5 (3-6.5) months after the last RTX infusion in patients with RA, and 5 (3-6.5) months in patients with AIDs. 5 patients (12.5%), 4 of them with neutrophils lower than 500/mm(3), developed a non-opportunistic serious infection and required antibiotics and granulocyte colony-stimulating factor injections, with a favourable outcome. After resolution of their RTX-related neutropenia, 19 patients (47.5%) were re-treated, and neutropenia reoccurred in 3 of them.

CONCLUSIONS: Late-onset neutropenia might occur after RTX and may result in serious infections. Thus, monitoring of white cell count should be performed after RTX. However, in this large registry of patients with AIDs, the frequency of RTX-induced neutropenia was much lower than that previously reported in patients treated for blood malignancies or AIDs.

Keywords: Autoimmune Diseases; Rheumatoid Arthritis; Treatment

References

  1. Haematologica. 2007 Feb;92(2):e20-3 - PubMed
  2. Ann Rheum Dis. 2013 Sep 1;72(9):1496-502 - PubMed
  3. QJM. 2012 Jun;105(6):545-50 - PubMed
  4. Semin Hematol. 2010 Apr;47(2):180-6 - PubMed
  5. Joint Bone Spine. 2008 Jun;75 Suppl 1:S1-99 - PubMed
  6. J Rheumatol. 2014 May;41(5):858-61 - PubMed
  7. Immunity. 1999 Apr;10(4):463-71 - PubMed
  8. Am J Hematol. 2010 Oct;85(10):810-2 - PubMed
  9. Rheumatology (Oxford). 2011 Jan;50(1):222-9 - PubMed
  10. Blood. 2003 Aug 15;102(4):1557-8 - PubMed
  11. Leuk Lymphoma. 2006 Jun;47(6):1013-7 - PubMed
  12. Blood. 2014 Jan 30;123(5):640-6 - PubMed
  13. Leuk Res. 2002 Jun;26(6):597-600 - PubMed
  14. Br J Dermatol. 2007 Dec;157(6):1271-3 - PubMed
  15. Arthritis Rheum. 2012 Feb;64(2):596-7; author reply 597 - PubMed
  16. Br J Dermatol. 2007 May;156(5):990-6 - PubMed
  17. Arthritis Rheum. 2010 Sep;62(9):2625-32 - PubMed
  18. Ann Rheum Dis. 2011 Jun;70(6):909-20 - PubMed
  19. J Clin Oncol. 2010 Jan 10;28(2):279-84 - PubMed
  20. Arthritis Rheum. 2011 Aug;63(8):2209-14 - PubMed
  21. N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 - PubMed

Publication Types